Territory of Excellence
Paris-Saclay Playground
Maturation of technologies
Technological projects portfolio
More about SATT Paris-Saclay
Optimize an innovation
Express an R&D need
More on our offers of services
Send an unsolicited application
Other request
NUTS-MAT
Curative therapy for pulmonary arterial hypertension
Investment: €652k
Scope: Healthcare
Scientific field(s): Biology and medicinal chemistry
Institution(s): Université Paris-Saclay - CEA - CNRS - Inserm
Development: Start-up in progress/completed
#PAHT #TherapeuticInnovation #First-In-ClassCandidate
Pulmonary arterial hypertension (PAHT) is a rare and incurable pulmonary vascular disease. Patients usually live 3 to 5 years following diagnosis. The causes of PAHT are multifactorial. The increase in pulmonary pressure is due to the uncontrolled proliferation of vascular cells that obstruct the pulmonary vessels and lead to death by right heart failure.
The therapies currently available are essentially vasodilators that address the consequences of the disease and do nothing to slow its progression.
In the case of therapeutic failure, heart-lung transplant or double lung transplant is the last recourse, but it is only possible for 50% of patients.
A new first-in-class therapeutic target involved in the vascular remodeling that causes PAHT has been identified.
The NUTS-MAT project aims to develop molecules that are antagonistic to this target and "smart" (they don't cross the blood-brain barrier), causing fewer side effects than traditional antagonists.
This innovative approach acts on the pulmonary vascular remodeling that causes PAHT.
The objective of the NUTS-MAT project is to position itself as a first-line treatment for pulmonary hypertension or as a supplement to current therapies, allowing patients to live with the illness long-term.
© 2023 SATT Paris-Saclay | Legal notices | Confidentiality policy | Marchés publics